All News

Alunbrig (brigatinib) was granted a supplemental new drug application for the treatment of patients with non-small cell lung cancer (NSCLC). Now, the drug can be administered via 180-mg tablets.

Combination therapy of Opdivo (nivolumab) and LAG-3 inhibitor relatlimab (BMS-986016) benefitted half of the patients with melanoma who previously progressed on an anti-PD-1 or anti-PD-L1 therapy, according to recent results from a dose-expansion study.

Two survivors investigate the frequency and availability of this post-cancer procedure.

Living life after the cure and coping with the complications of cancer

Adcetris (brentuximab vedotin) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the frontline treatment of patients who have classical Hodgkin lymphoma

Thank you for answering the questions below.

After years with few advancements, five new agents were approved to treat bladder cancer within the last year. CURE spoke with Terence Friedlander, M.D. about the shifting treatment paradigm for patients with the disease.

Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.

October can remind us of losses to our body, life roles, peers and other uncomfortable experiences we have yet to heal fully from.

I struggle with this month every year since my breast cancer.

Among 926 patients surveyed, where the median age was 58, 66 percent had previously used marijuana. Further, 24 percent used it in the last year and 21 percent in the past month.

PARP inhibitors are changing the way ovarian cancer is treated.

Living with lymphedema presents unique challenges. Here's one survivor's story.

Why did I react so differently from my family? It’s hard to put into words, but other survivors would just get it.

Some lessons I’ve learned on and off the operating table

More research is needed on the other genetic mutations, besides BRCA, that patients with ovarian cancer harbor so that they can be used to help plan treatments.

Verzenio (abemaciclib) was granted FDA approval for certain patients with advanced or metastatic breast cancer.

After nearly a decade with no new therapies, new drugs to treat liver cancer are showing great promise, according to Steven R. Alberts, M.D.

Do I really have to wear a prosthesis?

October is Breast Cancer Awareness Month, so be prepared to see pink everywhere you turn.

Expanding surveillance after surgery from chest X-ray to follow-up with PET-CT scan did not improve overall survival (OS), researchers reported during the 2017 ESMO Congress.

Experts in multiple myeloma share the newest information on the goals of therapy in symptomatic disease, testing for minimal residual disease, the role of transplantation, and the use of maintenance therapy.

Sumanta Kumar Pal, M.D., associate professor, Department of Medical Oncology, City of Hope, covered the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Acupuncture is a powerful resource that has been around for thousands of years. The traditional Chinese medicine is effective in treating chronic pain and headaches, and is now being used by many patients with cancer as a complementary therapy alongside medicinal treatment.

Claustrophobic, needle-phobic and just plain wimpy, the fight to survive has pulled me through.

Would you go see a genetics counselor again, now that there may be more to test for? Would you get a double mastectomy seven years out?